CAR T‐cell therapies are primarily designed to target diseases individually, and one study used ABE base editing to install a function‐preserving mutation that protects CAR T cells and healthy hematopoietic cells from the toxic effects of CD45 targeting, to develop universal CAR T‐cell therapies targeting panleukopoietic CD45 markers for AML, B‐cell lymphoma and acute T‐cell leukemia.330. The gene discussed is PTPRC; the disease is B-cell non-Hodgkin lymphoma.